Prostaglandin D2 metabolites activate asthmatic patient-derived type 2 innate lymphoid cells and eosinophils via the DP2 receptor

• Research
• Open Access
• 
  

• Saskia Carstensen, 
• Christina Gress, 
• Veit J. Erpenbeck, 
• Shamsah D. Kazani, 
• Jens M. Hohlfeld, 
• David A. Sandham & 
• Meike Müller 

Respiratory Research volume 22, Article number: 262 (2021) 

• details

Abstract

Background

Prostaglandin D2 (PGD2) signaling via prostaglandin D2 receptor 2 (DP2) contributes to atopic and non-atopic asthma. Inhibiting DP2 has shown therapeutic benefit in certain subsets of asthma patients, improving eosinophilic airway inflammation. PGD2 metabolites prolong the inflammatory response in asthmatic patients via DP2 signaling. The role of PGD2 metabolites on eosinophil and ILC2 activity is not fully understood.

Methods

Eosinophils and ILC2s were isolated from peripheral blood of atopic asthmatic patients. Eosinophil shape change, ILC2 migration and IL-5/IL-13 cytokine secretion were measured after stimulation with seven PGD2 metabolites in presence or absence of the selective DP2 antagonist fevipiprant.